Cancer Center Announcement

Brian J. Bolwell, MD Appointed Associate Director for the Taussig Cancer Institute

January 17, 2011

Dr. BolwellStan Gerson, MD, Director of the Case Comprehensive Cancer Center, announces the appointment of Brian J. Bolwell, MD as Associate Director for the Taussig Cancer Institute. Dr. Bolwell will join the senior leaders of the Cancer Center coordinating the overall cancer research effort of the 364 members of the Cancer Center who are faculty at CWRU, University Hospitals, and Cleveland Clinic.

In his position as Associate Director, Dr. Bolwell oversees the clinical research at the Taussig Cancer Institute and facilitates its coordination and integration with the scientific programs and clinical investigations taking place throughout the Cancer Center. Major elements of the clinical research program are efforts to increase investigator initiated clinical trials, overall accrual to clinical trials, and translational research with the basic science laboratories of the Taussig Cancer Institute.

Dr. Bolwell brings a wealth of experience to his current position. He received his BA from Harvard University and his medical degree from the CWRU School of Medicine. Following his internship and residency at University Hospitals of Cleveland, he did his fellowship in hematology and medical oncology at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Bolwell joined the faculty of the Cleveland Clinic in 1987, became the director of the bone marrow transplant program in 1988, and joined the Cleveland Clinic Board of Governors in 2004. Dr. Bolwell has served as Chairman of the Department of Hematologic Oncology and Blood Disorders since 2006, and Vice Chief of Staff since 2009. He is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and has been a member of the Case Comprehensive Cancer Center since its expansion to include the Cleveland Clinic in 2003. He has published approximately 150 papers in the areas of transplantation and hematologic malignancies, and is active in the clinical research programs in transplantation within the Stem Cell Program of the Cancer Center.